148 related articles for article (PubMed ID: 1350456)
1. Overexpression of the c-erbB-2 oncoprotein: why does this occur more frequently in ductal carcinoma in situ than in invasive mammary carcinoma and is this of prognostic significance?
Barnes DM; Bartkova J; Camplejohn RS; Gullick WJ; Smith PJ; Millis RR
Eur J Cancer; 1992; 28(2-3):644-8. PubMed ID: 1350456
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical demonstration of c-erbB-2 protein in mammary ductal carcinoma in situ.
Bartkova J; Barnes DM; Millis RR; Gullick WJ
Hum Pathol; 1990 Nov; 21(11):1164-7. PubMed ID: 1977679
[TBL] [Abstract][Full Text] [Related]
3. Nuclear and flow cytometric characteristics associated with overexpression of the c-erbB-2 oncoprotein in breast carcinoma.
Poller DN; Galea M; Pearson D; Bell J; Gullick WJ; Elston CW; Blamey RW; Ellis IO
Breast Cancer Res Treat; 1991 Dec; 20(1):3-10. PubMed ID: 1687505
[TBL] [Abstract][Full Text] [Related]
4. c-erbB-2 overexpression and histological type of in situ and invasive breast carcinoma.
Somerville JE; Clarke LA; Biggart JD
J Clin Pathol; 1992 Jan; 45(1):16-20. PubMed ID: 1346789
[TBL] [Abstract][Full Text] [Related]
5. Estrogen and progesterone receptor and c-erbB-2 oncoprotein analysis in pure in situ breast carcinoma: an immunohistochemical study.
Wilbur DC; Barrows GH
Mod Pathol; 1993 Mar; 6(2):114-20. PubMed ID: 8097877
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer.
Allred DC; Clark GM; Molina R; Tandon AK; Schnitt SJ; Gilchrist KW; Osborne CK; Tormey DC; McGuire WL
Hum Pathol; 1992 Sep; 23(9):974-9. PubMed ID: 1355464
[TBL] [Abstract][Full Text] [Related]
7. C-erbB-2 oncogene protein in in situ and invasive lobular breast neoplasia.
Porter PL; Garcia R; Moe R; Corwin DJ; Gown AM
Cancer; 1991 Jul; 68(2):331-4. PubMed ID: 1676930
[TBL] [Abstract][Full Text] [Related]
8. Expression of c-erbB-2 in in situ and in adjacent invasive ductal adenocarcinomas of the female breast.
Maguire HC; Hellman ME; Greene MI; Yeh I
Pathobiology; 1992; 60(3):117-21. PubMed ID: 1352687
[TBL] [Abstract][Full Text] [Related]
9. Oestrogen receptor expression in ductal carcinoma in situ of the breast: relationship to flow cytometric analysis of DNA and expression of the c-erbB-2 oncoprotein.
Poller DN; Snead DR; Roberts EC; Galea M; Bell JA; Gilmour A; Elston CW; Blamey RW; Ellis IO
Br J Cancer; 1993 Jul; 68(1):156-61. PubMed ID: 8100443
[TBL] [Abstract][Full Text] [Related]
10. Ideas in pathology. Ductal carcinoma in situ of the breast: a proposal for a new simplified histological classification association between cellular proliferation and c-erbB-2 protein expression.
Poller DN; Silverstein MJ; Galea M; Locker AP; Elston CW; Blamey RW; Ellis IO
Mod Pathol; 1994 Feb; 7(2):257-62. PubMed ID: 7911998
[TBL] [Abstract][Full Text] [Related]
11. [Expression of the c-erbB-2 oncoprotein in mammary Paget's disease. Immunohistochemical study by using 3 antibodies].
Edorh A; Parache RM; Migeon C; N'Sossani B; Rihn B
Pathol Biol (Paris); 1995 Sep; 43(7):584-9. PubMed ID: 8570262
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical distribution of c-erbB-2 in infiltrating and in situ breast cancer.
Gusterson BA; Machin LG; Gullick WJ; Gibbs NM; Powles TJ; Price P; McKinna A; Harrison S
Int J Cancer; 1988 Dec; 42(6):842-5. PubMed ID: 2903851
[TBL] [Abstract][Full Text] [Related]
13. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
Ottesen GL
APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968
[TBL] [Abstract][Full Text] [Related]
14. Endocrine ductal carcinoma in situ (E-DCIS) of the breast: a form of low-grade DCIS with distinctive clinicopathologic and biologic characteristics.
Tsang WY; Chan JK
Am J Surg Pathol; 1996 Aug; 20(8):921-43. PubMed ID: 8712293
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical evaluation of c-erbB-2 oncogene expression in ductal carcinoma in situ and atypical ductal hyperplasia of the breast.
Lodato RF; Maguire HC; Greene MI; Weiner DB; LiVolsi VA
Mod Pathol; 1990 Jul; 3(4):449-54. PubMed ID: 2170971
[TBL] [Abstract][Full Text] [Related]
16. p53 protein expression in human breast carcinoma: relationship to expression of epidermal growth factor receptor, c-erbB-2 protein overexpression, and oestrogen receptor.
Poller DN; Hutchings CE; Galea M; Bell JA; Nicholson RA; Elston CW; Blamey RW; Ellis IO
Br J Cancer; 1992 Sep; 66(3):583-8. PubMed ID: 1355662
[TBL] [Abstract][Full Text] [Related]
17. Expression of p53 protein in infiltrating and in-situ breast carcinomas.
Walker RA; Dearing SJ; Lane DP; Varley JM
J Pathol; 1991 Nov; 165(3):203-11. PubMed ID: 1684809
[TBL] [Abstract][Full Text] [Related]
18. C-erbB-2 protein and neuroendocrine expression in intraductal carcinomas of the breast.
Lilleng R; Hagmar BM; Nesland JM
Mod Pathol; 1992 Jan; 5(1):41-7. PubMed ID: 1347423
[TBL] [Abstract][Full Text] [Related]
19. Intraductal carcinoma (ductal carcinoma in situ) of the breast. A comparison of pure noninvasive tumors with those including different proportions of infiltrating carcinoma.
Moriya T; Silverberg SG
Cancer; 1994 Dec; 74(11):2972-8. PubMed ID: 7954261
[TBL] [Abstract][Full Text] [Related]
20. Expression of c-erbB3 protein in primary breast carcinomas.
Naidu R; Yadav M; Nair S; Kutty MK
Br J Cancer; 1998 Nov; 78(10):1385-90. PubMed ID: 9823984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]